PRG Science & Technology

2:30 PM - 2:45 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 104C
PRG S&Tech is a Korean company specializing in R&D for rare genetic diseases founded in 2017, and is identifying the cause of the disease and developing treatments based on it for patients suffering from rare genetic diseases with low demand.

Our core technology is a PPI (protein-protein interaction inhibitor) search method based on the pathogenesis of genetic diseases and a screening technology that secures hit materials through it.

Currently, we have nine treatment pipelines, and the main pipelines include HGPS (Hutchinson-Gilford Progeria Syndrome), WS (Werner Syndrome), ALS (Lou Gehrig), and NF2 (Neurofibromatosis Type 2).

If the safety of future treatment materials is secured through clinical trials, the indications for diseases can be expanded and applied to general aging-related diseases and degenerative neurological diseases, which are being researched and developed as a follow-up pipeline of our company.
Company Type:
Privately Funded Company
Company HQ State:
Company HQ Country:
Korea, Republic of
Year Founded:
September 29, 2017
Main Therapeutic Focus:
Orphan/Rare Diseases
Lead Product in Development:
HGPS(Hutchinson Gilford Progeria Syndrome) / WS(Werner Syndrome)
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4 (Treatment of HGPS, WS, ALS and NF2)
PRG Science & Technology